Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 51.93 - 132.99
Open     -
Vol / Avg. 0.00/755,672.00
Mkt cap 10.52B
P/E     -
Div/yield     -
EPS -2.05
Shares 84.28M
Beta 1.73
Inst. own 78%
Aug 5, 2015
Q2 2015 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 19, 2015
Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference
May 14, 2015
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Alnylam Pharmaceuticals Inc Earnings Call
May 7, 2015
Q1 2015 Alnylam Pharmaceuticals Inc Earnings Release
May 6, 2015
Alnylam Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 1, 2015
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Apr 21, 2015
Alnylam Pharmaceuticals Inc Call on 12-Month Patisiran Open- Label Extension Study Results for FAP treament
Apr 15, 2015
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference
Mar 20, 2015
Alnylam Pharmaceuticals Inc at Biocentury Future Leaders in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -273.92% -712.79%
Operating margin -281.72% -800.97%
EBITD margin - -777.39%
Return on average assets -15.04% -48.05%
Return on average equity -16.74% -59.74%
Employees 256 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi) in the United States. The Company’s Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia; ALN-TMP for the treatment of iron overload; ALN-CC5 for the treatment of C5 complement component mediated diseases, and GalNAc Conjugates. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01, ALN-VSP and ALN-HTT for the treatment of Huntington’s disease (HD). As of March 2014, the Company acquired Merck's subsidiary Sirna Therapeutics, Inc.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 61
Bio & Compensation  - Reuters